A retrospective comparative outcome analysis following systemic therapy in Mycosis fungoides and Sezary syndrome
| Autor: | Walter Hanel, Alexandra C. Hristov, Thomas F. Anderson, Charles W. Ross, Mark S. Kaminski, Ryan A. Wilcox, Robert Briski |
|---|---|
| Rok vydání: | 2016 |
| Předmět: |
0301 basic medicine
Oncology medicine.medical_specialty medicine.medical_treatment Disease 03 medical and health sciences Retinoids 0302 clinical medicine Photopheresis Mycosis Fungoides Internal medicine medicine Clinical endpoint T-cell lymphoma Humans Sezary Syndrome Retrospective Studies Chemotherapy Mycosis fungoides business.industry Retrospective cohort study Hematology Middle Aged medicine.disease Surgery Clinical trial Histone Deacetylase Inhibitors 030104 developmental biology Treatment Outcome 030220 oncology & carcinogenesis Interferons business |
| Zdroj: | American journal of hematology. 91(12) |
| ISSN: | 1096-8652 |
| Popis: | Cutaneous T-cell lymphomas (CTCL), with few exceptions, remain incurable and treatment is largely palliative. We performed a retrospective analysis of systemic treatment outcomes of patients diagnosed with MF/SS. We identified 223 patients with MF/SS evaluated at a single institution from 1997 to 2013. Disease stage at diagnosis, time of treatment, and treatments received were retrospectively analyzed using our CTCL database. The primary endpoint was time to next treatment (TTNT). Treatment outcomes were analyzed using Kaplan-Meier method and comparisons among groups were made using log-rank analysis. A superior TTNT was associated with retinoid or interferon therapies when compared with HDAC inhibitors or systemic chemotherapy. Retinoids and interferon were associated with superior TTNT in both limited-stage and advanced stage disease. Extracorporeal photophoresis (ECP) had a superior TTNT in Sezary Syndrome. HDAC inhibitors and chemotherapy were associated with inferior TTNT in both limited stage disease and advanced stage disease. With the exception of interferon, retinoids, or ECP, durable responses are rarely achieved with systemic therapies in MF/SS patients, particularly those with advanced-stage disease. Therefore, clinical trial participation with novel agents should be encouraged. Am. J. Hematol. 91:E491-E495, 2016. © 2016 Wiley Periodicals, Inc. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text